|
|||||
|
|
Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition study |
|
| Authors: | Thu Thi Pham Katharina Nimptsch Krasimira Aleksandrova Mazda Jenab Veronika Fedirko Kana Wu Anne Kirstine Eriksen Anne Tjønneland Gianluca Severi Joseph Rothwell Rudolf Kaaks Verena Katzke Alberto Catalano Claudia Agnoli Giovanna Masala Maria Santucci De Magistris Rosario Tumino Roel Vermeulen Amaia Aizpurua Camino Trobajo-Sanmartín María-Dolores Chirlaque Maria-Jose Sánchez Sai San Moon Lu Amanda J Cross Sofia Christakoudi Elisabete Weiderpass Tobias Pischon |
| Institution: | 1. Molecular Epidemiology Research Group, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany;2. Department of Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany
Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany;3. Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC-WHO), World Health Organization, Lyon, France;4. Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA;5. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;6. Danish Cancer Society Research Center, Copenhagen, Denmark;7. Danish Cancer Society Research Center, Copenhagen, Denmark Department of Public Health, University of Copenhagen, Copenhagen, Denmark;8. Université Paris-Saclay, UVSQ, Inserm “Exposome and Heredity” Team, Villejuif, France;9. Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;10. Centre for Biostatistics, Epidemiology, and Public Health, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy;11. Epidemiology and Prevention Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;12. Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy;13. Azienda Ospedaliera Universitaria (AOU) Federico II, Naples, Italy;14. Hyblean Association for Epidemiological Research, AIRE ONLUS, Ragusa, Italy;15. Institute of Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands;16. Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain;17. Instituto de Salud Pública y Laboral de Navarra, Pamplona, Spain Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain Navarre Institute for Health Research (IdiSNA), Pamplona, Spain;18. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain;19. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain Escuela Andaluza de Salud Pública (EASP), Granada, Spain Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain;20. Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden;21. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK;22. International Agency for Research on Cancer, World Health Organization, Lyon, France |
| Abstract: | Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine–Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73–1.23; Ptrend = .97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84–1.19; P = .98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression. |
| Keywords: | colorectal cancer EPIC mortality pre-diagnostic resistin survival |